small molecule

INVOKAMET

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Loss of exclusivityJuly 2030latest FDA-listed patent expiry

CompanyJanssen Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	INVOKAMET
Active ingredient	CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Strength	150MG;1GM
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	August 2014
Marketing status	RX

Listed patents

Patent	Expires	Type
11576894	July 2030	product
7943582*PED	August 2029	—
7943582	February 2029	substance, product
8513202*PED	June 2028	—
7943788*PED	January 2028	—
8513202	December 2027	substance, product
7943788	July 2027	substance, product

Regulatory exclusivity

Code	Expires
PED	June 2028
NPP	December 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Janssen Pharmaceuticals